A comparative study of efficacy and safety of drugs in stage I hypertensive patients attending cardiac OPD at tertiary care hospital
Doctor of Pharmacy, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR District, Pidathapolur, Nellore, Andhra Pradesh 52434, India.
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 26(02), 187–198.
Article DOI: 10.30574/gscbps.2024.26.2.0052
Publication history:
Received on 28 December 2023; revised on 31 January 2024; accepted on 03 February 2024
Abstract:
To study the efficacy and safety profile of Azilsartan 40 mg and Olmesartan 40 mg in stage I systemic Hypertension among patients attending cardiac OPD in a tertiary care center. All patients with stage I systemic hypertension of either sex, aged 20-65 years, with blood pressures of >140/90 mmHg or diabetes mellitus attending the cardiac outpatient. After initial screening, diagnosed cases of essential hypertension were randomly allocated to either group 1 (Tablet Azilsartan 40 mg or group 2 (Tablet Olmesartan 40 mg). The patients were advised to report for follow-up for review on the 4th, 8th, 12th, and 24th week.The mean decrease in the systolic blood pressure in both groups was statistically significant with a P value of <0.0000001. Both drugs controlled blood pressure at similar proportions. However, the mean of SBP and DBP for the Azilsartan group was lower than the Olmesartan Group. Both drugs were tolerated well, and no significant adverse effects were noted during the study.
Keywords:
Hypertension; Olmesartan; Azilsartan; Hospital
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
